IP Verse

Liposomes Having Useful N:P Ratio For Delivery Of Rna Molecules - EP2729126

The patent EP2729126 was granted to Glaxosmithkline on Dec 23, 2020. The application was originally filed on Jul 6, 2012 under application number EP12738679A. The patent is currently recorded with a legal status of "Revoked".

EP2729126

GLAXOSMITHKLINE
Application Number
EP12738679A
Filing Date
Jul 6, 2012
Status
Revoked
Sep 5, 2025
Grant Date
Dec 23, 2020
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions (5)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

ACUITAS THERAPEUTICSSep 23, 2021VOSSIUS & PARTNERADMISSIBLE
ACUITAS THERAPEUTICSSep 23, 2021VOSSIUS & PARTNER PATENTANWALTE RECHTSANWALTE MBBADMISSIBLE
MARGARET DIXONSep 23, 2021MEWBURN ELLISADMISSIBLE
MULLERSep 23, 2021MULLERADMISSIBLE
WEICKMANN & WEICKMANNSep 23, 2021WEICKMANN & WEICKMANN PARTMBBADMISSIBLE

Patent Citations (86) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication NumberPublication Link
DESCRIPTIONWO0202606
DESCRIPTIONWO0234771
DESCRIPTIONWO03018054
DESCRIPTIONWO2005002619
DESCRIPTIONWO2005032582
DESCRIPTIONWO2005111066
DESCRIPTIONWO2005113782
DESCRIPTIONWO2005121348
DESCRIPTIONWO2006089264
DESCRIPTIONWO2006091517
DESCRIPTIONWO2006110413
DESCRIPTIONWO2006138004
DESCRIPTIONWO2007049155
DESCRIPTIONWO2008020330
DESCRIPTIONWO2008137758
DESCRIPTIONWO2009016515
DESCRIPTIONWO2009031043
DESCRIPTIONWO2009086558
DESCRIPTIONWO2009104092
DESCRIPTIONWO2009109860
DESCRIPTIONWO2010119343
DESCRIPTIONWO2011005799
DESCRIPTIONWO2011076807
EXAMINATIONEP1392341
EXAMINATIONEP2130912
EXAMINATIONUS7422902
EXAMINATIONWO2005120152
EXAMINATIONWO2007107304
EXAMINATIONWO2008155141
EXAMINATIONWO2009086558
EXAMINATIONWO2009146867
EXAMINATIONWO2011005799
EXAMINATIONWO2011071860
EXAMINATIONWO2012006369
EXAMINATIONWO2012006372
EXAMINATIONWO2012006376
EXAMINATIONWO2012006378
EXAMINATIONWO9952503
INTERNATIONAL-SEARCH-REPORTUS5279833
INTERNATIONAL-SEARCH-REPORTWO03068190
INTERNATIONAL-SEARCH-REPORTWO2012031043
OPPOSITIONEP1764089
OPPOSITIONEP2590626
OPPOSITIONEP2590676
OPPOSITIONUS2006240554
OPPOSITIONUS2013225409
OPPOSITIONUS6815432
OPPOSITIONUS7422902
OPPOSITIONWO0209645
OPPOSITIONWO02098443
OPPOSITIONWO2005120152
OPPOSITIONWO2006078294
OPPOSITIONWO2007047749
OPPOSITIONWO2007107304
OPPOSITIONWO2008155141
OPPOSITIONWO2010042877
OPPOSITIONWO2011005799
OPPOSITIONWO2011008974
OPPOSITIONWO2011071860
OPPOSITIONWO2011076807
OPPOSITIONWO2013006825
OPPOSITIONWO9730170
OPPOSITIONWO9851278
OTHEREP1392341
OTHEREP2451475
OTHEREP2590626
OTHERUS2011117125
OTHERUS7422902
OTHERWO0061772
OTHERWO03023026
OTHERWO2005007689
OTHERWO2005120152
OTHERWO2006078294
OTHERWO2007047749
OTHERWO2007107304
OTHERWO2008155141
OTHERWO2009146867
OTHERWO2011005799
OTHERWO2011008974
OTHERWO2011071860
OTHERWO2012006369
OTHERWO2012006372
OTHERWO2012006376
OTHERWO2012006378
OTHERWO2012031043
OTHERWO9952503

Non-Patent Literature (NPL) Citations (52) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
DESCRIPTION- ARSHADY & GUYOT, Functional Polymer Colloids and Microparticles, CITUS BOOKS, (2002), vol. 4-
DESCRIPTION- GENNARO, Remington: The Science and Practice of Pharmacy. 20th edition,, (2000), ISBN 0683306472-
DESCRIPTION- GIULIANI ET AL., PROC NATL ACAD SCI USA, (2006), vol. 103, no. 29, pages 10834 - 9-
DESCRIPTION- GREGORIADIS, Liposome Technology, INFORMA HEALTHCARE, (2006), vol. I,II, II-
DESCRIPTION- Handbook of Experimental Immunology, SCIENTIFIC PUBLICATIONS, (1986), vol. I-IV-
DESCRIPTION- HEYES ET AL., J CONTROLLED RELEASE, (2005), vol. 107, pages 276 - 87-
DESCRIPTION- JEFFS ET AL., PHARMACEUTICAL RESEARCH, (2005), vol. 22, no. 3, pages 362 - 372-
DESCRIPTION- MARTINON ET AL., EUR J IMMUNOL, (1993), vol. 23, pages 1719 - 22-
DESCRIPTION- MAURER ET AL., BIOPHYSICAL JOURNAL, (2001), vol. 80, pages 2310 - 2326-
DESCRIPTION- S. COLOWICK AND N. KAPLAN, Methods In Enzymology, ACADEMIC PRESS, INC.-
DESCRIPTION- WEISSIG, Liposomes: Methods and Protocols, HUMANA PRESS, (2009), vol. 1-
DESCRIPTION- YONEYAMA; FUJITA, CYTOKINE & GROWTH FACTOR REVIEWS, (2007), vol. 18, pages 545 - 51-
EXAMINATION- Long Xu ET AL, "CLINICAL TRIALS AND TRANSLATIONAL MEDICINE COMMENTARY: Drug Delivery Trends in Clinical Trials and Translational Medicine: Challenges and Opportunities in the Delivery of Nucleic Acid-Based Therapeutics", Journal of Pharmaceutical Sciences, US, (20110101), vol. 100, no. 1, doi:10.1002/jps.22243, ISSN 0022-3549, pages 38 - 52, XP055483026
EXAMINATION- M Mockey ET AL, "mRNA-based cancer vaccine: prevention of B16 melanoma progression and metastasis by systemic injection of MART1 mRNA histidylated lipopolyplexes", Cancer Gene Therapy, (20070901), vol. 14, no. 9, doi:10.1038/sj.cgt.7701072, ISSN 0929-1903, pages 802 - 814, XP055007324
EXAMINATION- V V Kumar ET AL, "Single histidine residue in head-group region is sufficient to impart remarkable gene transfection properties to cationic lipids: evidence for histidine-mediated membrane fusion at acidic pH", Gene Therapy, GB, (20030801), vol. 10, no. 15, doi:10.1038/sj.gt.3301979, ISSN 0969-7128, pages 1206 - 1215, XP055483021
INTERNATIONAL-SEARCH-REPORT- CAPLEN N J, "Nucleic acid transfer using cationic lipids.", METHODS IN MOLECULAR BIOLOGY (CLIFTON, N.J.) 2000 LNKD- PUBMED:10561827, (2000), vol. 133, ISSN 1064-3745, pages 1 - 19, XP009162426 [I] 1-16 * page 1 * * page 3, 2nd paragraph and page 15, last paragraph, to page 16, first paragraph; page 9 - page 13 *-
INTERNATIONAL-SEARCH-REPORT- LONEZ C ET AL, "Cationic liposomal lipids: From gene carriers to cell signaling", PROGRESS IN LIPID RESEARCH, PERGAMON PRESS, PARIS, FR, vol. 47, no. 5, doi:10.1016/J.PLIPRES.2008.03.002, ISSN 0163-7827, (20080901), pages 340 - 347, (20080401), XP022715976 [A] 1-16 * abstract * * page 341, column 1, paragraph 4 - column 2, paragraph 1; figure 1 *
OPPOSITION- Anonymous, Chemical Book, (20210909), DLinDMA Properties, URL: https://www.chemicalbook.com/Search_EN.aspx?keyword=CB44797047, XP055847353-
OPPOSITION- Caplen N J, "Nucleic acid transfer using cationic lipids.", Methods in Molecular Biology, US, (20000101), vol. 133, ISBN 978-1-62703-541-5, pages 1 - 19, XP009162426-
OPPOSITION- Faneca H, Et Al, "Cationic Liposome-Based Systems for Nucleic Acid Delivery: From the Formulation Development to Therapeutic Applications", Drug Delivery Systems: Advanced Technologies Potentially Applicable in Personalised Treatment, Advances in Predictive, (20130101), vol. 4, pages 153 - 184, XP055849459-
OPPOSITION- HOERR INGMAR, "Stabilized messenger RNA (RNActive (TM)) as a tool for innovative gene delivery", TISSUE ENGINEERING, & 2ND INTERNATIONAL CONGRESS ON REGENERATIVE BIOLOGY/2ND INTERNATIONAL CONGRESS ON BIO-NANO-INTERFACE; STUTTGART, GERMANY; OCTOBER 09 -11, 2006, & 2ND INTERNATIONAL CONGRESS ON REGENERATIVE BIOLOGY/2ND INTERNATIONAL CONGRESS ON BIO-NANO-INTERFACE; STUTTGART, GERMANY; OCTOBER 09 -11, 2006, (20070401), vol. 13, no. 4, pages 886 - 887, XP009125215-
OPPOSITION- Ju Jia, Et Al, "Novel Cholesterol-Based Cationic Lipids as Transfecting Agents of DNA for Efficient Gene Delivery", Int. J. Mol. Sci., (20150101), vol. 16, pages 5666 - 5681, XP055849473-
OPPOSITION- LU D et al., Cancer Gene Therapy, (19940000), vol. 1, no. 4, pages 245 - 252, XP008029614-
OPPOSITION- MacLachlan I., "Liposomal formulations for nucleic acid delivery", MacLachlan I., CROOKE STANLEY T, ANTISENSE DRUG TECHNOLOGY:PRINCIPLES, STRATEGIES, AND APPLICATIONS, US, CRC PRESS, (20070101), pages 237 - 270, ISBN 978-0-8493-8796-8, XP002584305-
OPPOSITION- MOCKEY M et al., Cancer Gene Therapy, (20070000), vol. 14, pages 802 - 814, XP002666288-
OPPOSITION- "New Histidylated Cationic Lipids for DNA- and mRNA- Based Lipofection", Molecular Therapy, Elsevier Inc., US, US, (20040501), vol. 9, ISSN 1525-0016, pages 258 - 259, XP004635048-
OPPOSITION- Stryer Lubert, "Biochemistry. Passage", (19950101), page 23, XP055849461-
OPPOSITION- UDDIN SN, Biotechnology and Molecular Biology Review, (20070000), vol. 2, no. 3, pages 058 - 067, XP055069508-
OPPOSITION- Yu Jinxiang, Anchordoquy Thomas, "Effects of Moisture Content on the Storage Stability of Dried Lipoplex Formulations", Journal of Pharmaceutical Sciences, (20090901), vol. 98, no. 9, pages 3278 - 3289, XP055849463-
OPPOSITION- TRANCHANT ISABELLE, ET AL, "Physicochemical optimisation of plasmid delivery by cationic lipids.", The Journal of Gene Medicine, US, (20040201), vol. 6 Suppl 1, doi:10.1002/jgm.509, ISSN 1099-498X, pages S24 - S35, XP002521501
OPPOSITION- Barichello José Mario, Ishida Tatsuhiro, Kiwada Hiroshi, "Complexation of siRNA and pDNA with Cationic Liposomes: The Important Aspects in Lipoplex Preparation", Barichello José Mario, Ishida Tatsuhiro, Kiwada Hiroshi, Biji T. KurienR. Hal Scofield, Protein Electrophoresis, US, New York ; Heidelberg [u.a.] : Humana Press,, (20100101), vol. 605, pages 461 - 472, doi:10.1007/978-1-60327-360-2_32, ISSN 1064-3745, ISBN 978-1-60761-961-1, XP055847322
OPPOSITION- RODRIGUEZA WET et al., Cancer Chemother Pharmacol, (20140000), vol. 74, pages 151 - 166, XP055128361
OPPOSITION- MAHATO RI, "Water insoluble and soluble lipids for gene delivery", Adv Drug Deliv Rev, (20050405), vol. 57, no. 5, doi:10.1016/j.addr.2004.12.005, pages 699 - 712, XP025283906
OPPOSITION- TANNOUS BA et al., "Secreted blood reporters: Insights and applications", Biotechnol Adv, (20110908), vol. 29, no. 6, doi:10.1016/j.biotechadv.2011.08.021, pages 997 - 1003, XP028306433
OPPOSITION- Spelios, M. Nedd, S. Matsunaga, N. Savva, M., "Effect of spacer attachment sites and pH-sensitive headgroup expansion on cationic lipid-mediated gene delivery of three novel myristoyl derivatives", Biophysical Chemistry, ELSEVIER, AMSTERDAM, NL, NL, (20070807), vol. 129, no. 2-3, doi:10.1016/j.bpc.2007.05.016, ISSN 0301-4622, pages 137 - 147, XP022189754
OPPOSITION- Saxena, S. ; Sonwane, A.A. ; Dahiya, S.S. ; Patel, C.L. ; Saini, M. ; Rai, A. ; Gupta, P.K., "Induction of immune responses and protection in mice against rabies using a self-replicating RNA vaccine encoding rabies virus glycoprotein", VETERINARY MICROBIOLOGY, NL, (20090414), vol. 136, no. 1-2, doi:10.1016/j.vetmic.2008.10.030, ISSN 0378-1135, pages 36 - 44, XP026071306
OPPOSITION- XU Y et al., "Physicochemical characterization and purification of cationic lipoplexes", Biophys J, (19990700), vol. 77, no. 1, pages 341 - 353, XP055847325
OPPOSITION- NARANG A S, ET AL., "Cationic Lipids with Increased DNA Binding Affinity for Nonviral Gene Transfer in Dividing and Nondividing Cells", BIOCONJUGATE CHEM., (20050101), vol. 16, no. 1, doi:10.1021/BC049818Q, pages 156 - 168, XP002544960
OPPOSITION- LIU YANG, HUANG LEAF, "Designer Lipids Advance Systemic siRNA Delivery", Molecular Therapy, US, (20100401), vol. 18, no. 4, doi:10.1038/MT.2010.39, ISSN 1525-0016, pages 669 - 670, XP002684383
OPPOSITION- Sean C Semple, Akin Akinc, Jianxin Chen, Ammen P Sandhu, Barbara L Mui, Connie K Cho, Dinah W Y Sah, Derrick Stebbing, Erin J Crosley, Ed Yaworski, et al., "Rational design of cationic lipids for siRNA delivery", Nature Biotechnology, Gale Group Inc., New York, New York, (20100201), vol. 28, no. 2, doi:10.1038/NBT.1602, ISSN 1087-0156, pages 172 - 176, XP002633693
OPPOSITION- SEMPLE S et al., Nat Biotechnol, vol. 28, no. 2, (20100000), pages 172 - 176, XP002633693
OPPOSITION- Gao H; Hui K M, "Synthesis of a novel series of cationic lipids that can act as efficient gene delivery vehicles through systematic heterocyclic substitution of cholesterol derivatives.", Gene Therapy, Nature Publishing Group, London, GB, GB, (20010601), vol. 8, no. 11, doi:10.1038/sj.gt.3301471, ISSN 0969-7128, pages 855 - 863, XP009110821
OPPOSITION- MALONE R. W., FELGNER P. L., VERMA I. M., "CATIONIC LIPOSOME-MEDIATED RNA TRANSFECTION.", Proceedings of the National Academy of Sciences, National Academy of Sciences, US, US, (19890801), vol. 86., no. 16., doi:10.1073/pnas.86.16.6077, ISSN 0027-8424, pages 6077 - 6081., XP000604642
OPPOSITION- BETTINGER T et al., Nucleic Acids Research, (20010000), vol. 29, no. 18, pages 3882 - 3891, XP002374430
OPPOSITION- Qing-Qing Zhao, Jin-Liang Chen,A,# Teng-Fei Lv,A Cai-Xia He,A Gu-Ping Tang,B Wen-Quan Liang,A Yasuhiko Tabata,C And Jian-Qing Gao, "N/P Ratio Significantly Influences the Transfection Efficiency and Cytotoxicity of a Polyethylenimine/Chitosan/DNA Complex", Biol. Pharm. Bull., Pharmaceutical Society of Japan, doi:10.1248/bpb.32.706, (20090401), pages 706 - 710, Biol. Pharm. Bull., URL: http://www.jstage.jst.go.jp/article/bpb/32/4/706/_pdf, (20120329), XP055023364
OPPOSITION- Pascolo S, "Vaccination with messenger RNA", METHODS IN MOLECULAR MEDICINE, (20060101), ISSN 1543-1894, pages 23 - 40, XP009117840
OPPOSITION- Lin Zhu, Ram I Mahato, "Lipid and polymeric carrier-mediated nucleic acid delivery", Expert Opinion on Drug Delivery, GB, (20101001), vol. 7, no. 10, doi:10.1517/17425247.2010.513969, ISSN 1742-5247, pages 1209 - 1226, XP055352907
OTHER- "Case Law of the Boards of Appeal", G/05, Gl/06; Guidelines for Examination-
OTHER- MOCKEY, M. et al., "mRNA-based cancer vaccine: prevention of B16 melanoma progression and metastasis by systemic injection of MART1 mRNA histidylated lipopolyplexes", Cancer Gene Therapy, (20070622), vol. 14, no. 9, pages 802 - 814, XP002666288-
OTHER- XU, L. et al., "Drug delivery trends in clinical trials and translational medicine: Challenges and opportunities in the delivery of nucleic acid-based therapeutics", J Pharm Sci., (20110100), vol. 100, no. 1, pages 38 - 52, XP055044014
OTHER- SEMPLE et al., "Rational design of cationic lipids for sirna delivery", Nature Biotechnology, (20100117), vol. 28, no. 2, pages 172 - 176, XP002633693
OTHER- KUMAR, V. et al., "SINGLE HISTIDINE RESIDUE IN HEAD-GROUP REGION IS SUFFICIENT TO IMPART REMARKABLE GENE TRANSFECTION PROPERTIES TO CATIONIC LIPIDS: EVIDENCE FOR HISTIDINE-MEDIATED MEMBRANE FUSION AT ACIDC pH", Gene Therapy, (20030000), vol. 10, no. 15, pages 1206 - 1215, XP003002109

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents